| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FLT4 |
| Uniprot No | P35916 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-776aa |
| 氨基酸序列 | YSMTPPTLNITEESHVIDTGDSLSISCRGQHPLEWAWPGAQEAPATGDKDSEDTGVVRDCEGTDARPYCKVLLLHEVHANDTGSYVCYYKYIKARIEGTTAASSYVFVRDFEQPFINKPDTLLVNRKDAMWVPCLVSIPGLNVTLRSQSSVLWPDGQEVVWDDRRGMLVSTPLLHDALYLQCETTWGDQDFLSNPFLVHITGNELYDIQLLPRKSLELLVGEKLVLNCTVWAEFNSGVTFDWDYPGKQAERGKWVPERRSQQTHTELSSILTIHNVSQHDLGSYVCKANNGIQRFRESTEVIVHENPFISVEWLKGPILEATAGDELVKLPVKLAAYPPPEFQWYKDGKALSGRHSPHALVLKEVTEASTGTYTLALWNSAAGLRRNISLELVVNVPPQIHEKEASSPSIYSRHSRQALTCTAYGVPLPLSIQWHWRPWTPCKMFAQRSLRRRQQQDLMPQCRDWRAVTTQDAVNPIESLDTWTEFVEGKNKTVSKLVIQNANVSAMYKCVVSNKVGQDERLIYFYVTTIPDGFTIESKPSEELLEGQPVLLSCQADSYKYEHLRWYRLNLSTLHDAHGNPLLLDCKNVHLFATPLAASLEEVAPGARHATLSLSIPRVAPEHEGHYVCEVQDRRSHDKHCHKKYLSVQALEAPRLTQNLTDLLVNVSDSLEMQCLVAGAHAPSIVWYKDERLLEEKSGVDLADSNQKLSIQRVREEDAGRYLCSVCNAKGCVNSSASVAVEGSEDKGSMEI |
| 分子量 | 89.1 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人FLT4(VEGFR-3)蛋白的参考文献示例，内容基于典型研究方向整理：
1. **"Recombinant Expression and Functional Analysis of Human VEGFR-3 in Mammalian Cells"**
*作者：Zhang et al., 2020*
**摘要**：该研究成功在HEK293细胞中表达了具有生物活性的重组人FLT4蛋白，并证实其与配体VEGF-C的结合能力，为后续受体功能研究提供了工具。
2. **"Structural Insights into the Extracellular Domain of VEGFR-3 through Crystallography"**
*作者：Wang et al., 2021*
**摘要**：通过X射线晶体学解析了FLT4胞外结构域的三维结构，揭示了其与VEGF-C结合的分子机制，为靶向药物设计奠定基础。
3. **"FLT4-Fc Fusion Protein Attenuates Lymphangiogenesis in Tumor Metastasis Models"**
*作者：Lee et al., 2018*
**摘要**：构建了FLT4-Fc重组融合蛋白，证明其可通过竞争性抑制VEGF-C信号通路，显著抑制小鼠肿瘤模型的淋巴管生成和转移。
4. **"Therapeutic Potential of Soluble VEGFR-3 in Lymphedema Treatment"**
*作者：Smith et al., 2019*
**摘要**：研究表明，可溶性重组FLT4蛋白能够改善实验性淋巴水肿模型的淋巴回流功能，提示其作为治疗性蛋白的应用前景。
*注：以上文献为示例性概括，实际引用时建议通过学术数据库(如PubMed、Web of Science)核实具体文献信息。*
Recombinant human FLT4 protein, also known as vascular endothelial growth factor receptor 3 (VEGFR-3), is a key transmembrane tyrosine kinase receptor involved in regulating lymphangiogenesis and angiogenesis. FLT4 binds to ligands VEGF-C and VEGF-D, triggering dimerization, autophosphorylation, and activation of downstream signaling pathways such as PI3K-Akt and MAPK, which promote endothelial cell proliferation, survival, and migration. During embryonic development, FLT3 is critical for the formation of the lymphatic system. In adults, it is predominantly expressed in lymphatic endothelial cells but is upregulated in pathological conditions, including tumor angiogenesis, metastasis, and lymphedema, making it a therapeutic target for cancer and lymphatic disorders.
Produced via mammalian expression systems (e.g., CHO or HEK293 cells), recombinant FLT4 retains post-translational modifications, ensuring structural and functional fidelity. It serves as a decoy receptor to inhibit VEGF-C/VEGF-D-mediated signaling, thereby suppressing lymphangiogenesis and tumor progression. Additionally, it is utilized in drug discovery, antibody development, and mechanistic studies to elucidate ligand-receptor interactions and signaling cascades. Its role in disease pathogenesis and therapeutic potential continues to drive research in oncology and vascular biology.
×
